At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 415 enrolled
Drug / intervention
BOL-303242-X +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
In Brief
A Phase 2 clinical trial evaluating BOL-303242-X and Vehicle for BOL-303242-X for Cataract and Inflammation. Completed, enrolled 415 participants across 1 site.
Detailed Summary
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract, Inflammation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJun 2009
Primary CompletionMar 2010
Study CompletionMay 2010
TodayJul 2026
First PostedMay 20, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.1 years ago
Interventions
BOL-303242-Xdrug
Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
Vehicle for BOL-303242-Xdrug
Medication instilled into the study eye, subjects randomized to various drug dose schedules.